Skip to main content
. Author manuscript; available in PMC: 2017 Jul 6.
Published in final edited form as: Lancet Oncol. 2016 Feb 6;17(3):299–308. doi: 10.1016/S1470-2045(15)00544-6

Figure 3. Antitumour activity according to PD-L1 status (response evaluable population with ≥24 weeks follow-up).

Figure 3

Figure 3

Change in tumour size from baseline in (A) PD-L1− patients (PD-L1 <25%), (B) PD-L1+ patients (PD-L1 ≥25%), (C) patients with unknown PD-L1 status; (D) Best change in tumour size by PD-L1 status. D=durvalumab; na=status unknown; PD- L1=programmed cell death ligand-1; Q=every; T=tremelimumab; W=weeks.